Abstract
uMPM is associated with poor prognosis and high burden of disease with a high need for new therapeutic options. CheckMate-743 (NCT02899299) has demonstrated survival and quality of life benefits for nivolumab plus ipilimumab vs. pemetrexed plus cisplatin/carboplatin (chemotherapy) as first-line (1L) treatment in uMPM. Nivolumab+ipilimumab is the new standard of care for 1L treatment in the recent ESMO and Dutch guidelines. To assess the long-term survival and economic benefits, we conducted a cost-effectiveness analysis of nivolumab+ipilimumab vs. chemotherapy for 1L uMPM in the Netherlands for the overall population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
